[Rheumatism therapy, from the economic viewpoint. COX-2 inhibitor as cost saving drug].
D001172:Arthritis, Rheumatoid / Q000191:economics*; D000068579:Celecoxib; D017046:Cost Savings; D016861:Cyclooxygenase Inhibitors / Q000191:economics*; D016527:Drug Costs; D005858:Germany; D007783:Lactones / Q000191:economics*; D011720:Pyrazoles; D013449:Sulfonamides / Q000191:economics*; D013450:Sulfones
D016861:Cyclooxygenase Inhibitors; D007783:Lactones; D011720:Pyrazoles; D013449:Sulfonamides; D013450:Sulfones; C116926:rofecoxib; D000068579:Celecoxib